Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ADVM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ADVM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Adverum Biotechnologies Inc

ADVM
Current price
2.28 USD +0.02 USD (+0.88%)
Last closed 2.26 USD
ISIN US00773U2078
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 47 630 796 USD
Yield for 12 month -68.25 %
1Y
3Y
5Y
10Y
15Y
ADVM
21.11.2021 - 28.11.2021

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Address: 100 Cardinal Way, Redwood City, CA, United States, 94063

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

19.75 USD

P/E Ratio

Dividend Yield

Financials ADVM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ADVM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 000 000 USD

Last Year

+3 600 000 USD

Current Quarter

-3 600 000 USD

Last Quarter

Current Year

-2 653 000 USD

Last Year

-2 044 000 USD

Current Quarter

-10 643 000 USD

Last Quarter

EBITDA -154 842 000 USD
Operating Margin TTM -15 818.10 %
Price to Earnings
Return On Assets TTM -48.76 %
PEG Ratio
Return On Equity TTM -144.51 %
Wall Street Target Price 19.75 USD
Revenue TTM 1 000 000 USD
Book Value 1.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -70.00 %
Dividend Yield
Gross Profit TTM -89 378 000 USD
Earnings per share -7.22 USD
Diluted Eps TTM -7.22 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ADVM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 57.73
Price Sales TTM 47.63
Enterprise Value EBITDA 0.099
Price Book MRQ 1.80

Technical Indicators ADVM

For 52 Weeks

1.78 USD 10.14 USD
50 Day MA 2.57 USD
Shares Short Prior Month 1 943 834
200 Day MA 4.79 USD
Short Ratio 5.99
Shares Short 1 843 405
Short Percent 10.07 %